Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 14/20 | 0.45 |
| ▸ | RARA | P10276 | 1/20 | 0.44 |
| ▸ | RARB | P10826 | 1/20 | 0.44 |
| ▸ | RARG | P13631 | 1/20 | 0.44 |
| ▸ | ITK | Q08881 | 1/20 | 0.42 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.41 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.41 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1262354 | 0.90 | ITK (0.43) | GCKRARARARBRARGITK | |
| SCHEMBL1262260 | 0.83 | GCK (0.47) | GCKRARARARBRARGCSNK2A2 | |
| SCHEMBL1263091 | 0.82 | GCK (0.45) | GCKRARARARBRARGCSNK2A2 | |
| SCHEMBL1261560 | 0.81 | CDK2 (0.49) | GCKRARARARBRARGITK | |
| SCHEMBL2664723 | 0.80 | GCK (0.51) | GCKRARARARBRARGCSNK2A2 | |
| SCHEMBL1262356 | 0.79 | GCK (0.43) | GCKRARARARBRARGITK | |
| SCHEMBL1261486 | 0.79 | GCK (0.47) | GCKRARARARBRARGCSNK2A2 | |
| SCHEMBL1261642 | 0.77 | GCK (0.56) | GCKRARARARBRARGCSNK2A2 | |
| SCHEMBL1262312 | 0.76 | GCK (0.55) | GCKRARARARBRARGCSNK2A2 | |
| SCHEMBL1262938 | 0.76 | GCK (0.55) | GCKCSNK2A2CSNK2A1CCNE1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110230529-A1 | BENZAMIDE GLUCOKINASE ACTIVATORS | TRANSTECH PHARMA, INC. (US) | 2011-09-22 | — | — | US | disclosed |
| US-7880012-B2 | e.g. 3-[2-(3-Isopropoxy-5-phenoxy-benzoylamino)-thiazol-5-yl-sulfanyl]-propionic acid methyl ester; metabolic disorder, blood glucose lowering, hyperglycemia, impaired glucose tolerance (IGT), Syndrome X, Polycystic Ovarian Syndrome, type I and type II diabetes, dyslipidemia, hyperlipidemia etc. | TRANSTECH PHARMA, INC. (US) | 2011-02-01 | — | — | US | disclosed |
| US-20090176991-A1 | BENZAMIDE GLUCOKINASE ACTIVATORS | TRANSTECH PHARMA, LLC | 2009-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176991-A1 | BENZAMIDE GLUCOKINASE ACTIVATORS | GCK, GCKR, KHK | GCK 1/4885RARA 3803/4885RARB 4051/4885 |
| US-20110230529-A1 | BENZAMIDE GLUCOKINASE ACTIVATORS | GCK, GCKR, KHK | GCK 1/4885RARA 3803/4885RARB 4051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.